Tips on Finding Insurance Coverage for Cancer Rehabilitation
July 02, 2012 – Kathy LaTour
Recognizing Actinic Keratosis
June 19, 2012 – Jon Garinn
Two Congressional Bills on Colorectal Cancer Introduced
June 19, 2012 – Lena Huang
We Do Harm: A Doctor Breaks Ranks About Being Sick in America
June 15, 2012 – Katherine Lagomarsino
Finalist Esssay: Not Just a Nurse, But Also an Angel
June 15, 2012 – Cesar Quesada
Finalist Essay: My Christmas Carol
June 14, 2012 – Wendy Crowther
Long-Term Estrogen-Only Hormone Therapy Increases Breast Cancer Risk
June 13, 2012 – Elizabeth Whittington
Breast Cancer Call to Rehabilitation & Exercise Action
June 16, 2012 – Kathy LaTour
Is Rehabilitation Right for You?
June 16, 2012 – Kathy LaTour
Prevention is the Best Medicine When It Comes to HPV
June 16, 2012 – Charlotte Huff
First Steps: Vaccine Research
June 15, 2012 – Elizabeth Whittington
Myths About the Dying Process
June 16, 2012
Expressing Oneís Thoughts
June 16, 2012 – Katy Human
Rx-Fueled Anger
June 15, 2012 – Heather L. Van Epps, PhD
Questions to Ask About a Clinical Trial
June 16, 2012 – Paul Engstrom
Better, Stronger, Happier
June 16, 2012 – Carole Schneider, PhD
Pipeline
June 13, 2012 – Lindsay Ray
My Oncology Angel
June 14, 2012 – Greg Schilling
Sweet Relief: Could Chocolate Prevent Cancer?
June 14, 2012 – Melissa Gaskill
EPA Plans to Cut Radon Program, Despite Continued Cancer Risk
June 16, 2012 – Jane Hill
Light Bright: Awareness of Skin Sensitivity
June 12, 2012 – Lacey Meyer
Shifts in Causation, Biology and Treatment of Head and Neck Cancer
June 13, 2012 – Debu Tripathy, MD
Comments from our Readers
June 14, 2012
Cruciferous Veggies May Ward Off Recurrence
June 15, 2012 – Kathy LaTour
Q&A: Counterfeit Chemotherapy Drugs Cause Concern
June 16, 2012 – Len Lichtenfeld, MD
CT Challenge Survivorship Summit
June 16, 2012 – Jon Garinn
Swift Thanks Absentee Date at ACM Awards
June 15, 2012 – Lindsay Ray
Leukemia Survival Rates Greatly Improved, Study Says
June 16, 2012 – Katherine Lagomarsino
ASCO Updates
June 12, 2012 – Staff Reports
Letting Go: Saying Goodbye When a Loved One Says Itís Time
June 13, 2012 – Don Vaughan
The Write Stuff: Expressive Writing About Cancer Promotes Healing and Well-Being
June 11, 2012 – Katy Human
Seeing Red: Coping with Anger During Cancer
June 10, 2012 – Heather L. Van Epps, PhD
Trials & Tribulations: Pursuing a Clinical Trial Requires Determination and Education
June 11, 2012 – Paul Engstrom
Road to Recovery: Cancer Rehab Defines the New Normal
June 10, 2012 – Kathy LaTour
Facing the Facts: HPV-Associated Head and Neck Cancers Get a Second Look
June 15, 2012 – Charlotte Huff
Calling Cancer's Bluff: Research in Vaccine Therapy for Cancer Is Paying Off
June 11, 2012 – Laura Beil
Tips on Finding Insurance Coverage for Cancer Rehabilitation
July 02, 2012 – Kathy LaTour
Recognizing Actinic Keratosis
June 19, 2012 – Jon Garinn
Two Congressional Bills on Colorectal Cancer Introduced
June 19, 2012 – Lena Huang
We Do Harm: A Doctor Breaks Ranks About Being Sick in America
June 15, 2012 – Katherine Lagomarsino
Finalist Esssay: Not Just a Nurse, But Also an Angel
June 15, 2012 – Cesar Quesada
Finalist Essay: My Christmas Carol
June 14, 2012 – Wendy Crowther
Long-Term Estrogen-Only Hormone Therapy Increases Breast Cancer Risk
June 13, 2012 – Elizabeth Whittington
Breast Cancer Call to Rehabilitation & Exercise Action
June 16, 2012 – Kathy LaTour
Is Rehabilitation Right for You?
June 16, 2012 – Kathy LaTour
Prevention is the Best Medicine When It Comes to HPV
June 16, 2012 – Charlotte Huff
First Steps: Vaccine Research
June 15, 2012 – Elizabeth Whittington
Myths About the Dying Process
June 16, 2012
Expressing Oneís Thoughts
June 16, 2012 – Katy Human
Rx-Fueled Anger
June 15, 2012 – Heather L. Van Epps, PhD
Questions to Ask About a Clinical Trial
June 16, 2012 – Paul Engstrom
Better, Stronger, Happier
June 16, 2012 – Carole Schneider, PhD
Pipeline
June 13, 2012 – Lindsay Ray
My Oncology Angel
June 14, 2012 – Greg Schilling
Sweet Relief: Could Chocolate Prevent Cancer?
June 14, 2012 – Melissa Gaskill
EPA Plans to Cut Radon Program, Despite Continued Cancer Risk
June 16, 2012 – Jane Hill
Light Bright: Awareness of Skin Sensitivity
June 12, 2012 – Lacey Meyer
Shifts in Causation, Biology and Treatment of Head and Neck Cancer
June 13, 2012 – Debu Tripathy, MD
Comments from our Readers
June 14, 2012
Cruciferous Veggies May Ward Off Recurrence
June 15, 2012 – Kathy LaTour
Q&A: Counterfeit Chemotherapy Drugs Cause Concern
June 16, 2012 – Len Lichtenfeld, MD
CT Challenge Survivorship Summit
June 16, 2012 – Jon Garinn
Swift Thanks Absentee Date at ACM Awards
June 15, 2012 – Lindsay Ray
Leukemia Survival Rates Greatly Improved, Study Says
June 16, 2012 – Katherine Lagomarsino
ASCO Updates
June 12, 2012 – Staff Reports
Letting Go: Saying Goodbye When a Loved One Says Itís Time
June 13, 2012 – Don Vaughan
The Write Stuff: Expressive Writing About Cancer Promotes Healing and Well-Being
June 11, 2012 – Katy Human
Seeing Red: Coping with Anger During Cancer
June 10, 2012 – Heather L. Van Epps, PhD
Currently Viewing
Trials & Tribulations: Pursuing a Clinical Trial Requires Determination and Education
June 11, 2012 – Paul Engstrom
Facing the Facts: HPV-Associated Head and Neck Cancers Get a Second Look
June 15, 2012 – Charlotte Huff
Calling Cancer's Bluff: Research in Vaccine Therapy for Cancer Is Paying Off
June 11, 2012 – Laura Beil

Trials & Tribulations: Pursuing a Clinical Trial Requires Determination and Education

Patients often find clinical trial restrictions make it difficult to participate.

BY Paul Engstrom
PUBLISHED June 11, 2012

After receiving a cancer diagnosis, some patients want to consider every option before deciding on treatment. Rather than waiting to enroll in a clinical trial as a last resort, they may be willing to explore the possibility upfront, seeking trials that include standard treatment in addition to the experimental approach. But identifying and ultimately participating in a study can be a challenge. Beyond learning the potential risks and benefits, patients should also understand the barriers around becoming involved.

Patients may be reluctant to participate in trials for a variety of reasons—they feel they don’t know enough, they might not meet strict eligibility requirements or they worry about how to cover the costs. Yet, as strange as it may seem, physicians are often a roadblock between patients and  trials. According to a 2010 report by the Institute of Medicine, primary care doctors might not mention cancer trials as a possibility because, as generalists, they often are unfamiliar with them—understandable, considering the National Institutes of Health track more than 122,000 clinical trials in 179 countries.

Oncologists might not mention them either—or may even discourage participation—if they object to less traditional treatments or worry about the additional time, cost and paperwork burdens they would bear on behalf of patients who enroll, a legitimate concern in this age of financially squeezed healthcare. A survey published in 2011 in the Journal of Oncology Practice found that 44 percent of 213 trial-eligible cancer patients did not recall discussing trials with their doctor.

If a patient’s oncologist doesn’t mention trials or balks at the subject, the patient should get a second opinion, says Richard Schilsky, MD, section chief of hematology/oncology at The University of Chicago Medicine, noting that an oncologist once advised one of his own family members not to become a “guinea pig.”

“Second opinions are worthwhile. Patients deserve to hear different points of view and have as much information as possible,” Schilsky says. “We know that patients have strong emotional attachments to their physicians; sometimes it’s a doctor they’ve been with for a long time. But at the end of the day, patients must do what hopefully will be best for them.”

Even if the patient’s oncologist is cooperative, finding an appropriate trial—much less one within a reasonable geographic distance—can be daunting, given every patient’s unique medical history, disease variables, demographic characteristics, eligibility criteria and the vast array of trials. David Spigel, MD, a clinical oncologist and director for the Lung Cancer Research Program at the Sarah Cannon Research Institute in Nashville, Tenn., encourages his patients to explore clinical trials databases on their own first. Later, during his free time, he digs through and narrows their findings to one or more studies he believes are most applicable—in effect, working as a translator, navigator and advocate for the patient.

“It helps me find a way to help,” Spigel says. “That makes things easier for everybody.”

[Read "Recruiting for Clinical Trials Takes Center Stage"]

Although no centralized, searchable database with up-to-the-minute information exists, the most comprehensive one is ClinicalTrials.gov from the National Institutes of Health. Others include the National Cancer Institute’s (NCI) list; TrialCheck.org, developed by the Coalition of Cancer Cooperative Groups; proprietary databases at drug and biotechnology companies; and the International Federation of Pharmaceutical Manufacturers & Associations Clinical Trials Portal.

Databases can be difficult to navigate, even though most provide instructions. It helps if patients know all the details of their disease and any prior treatments before searching, so they can correctly refine the search parameters. The NCI also provides live help online and by phone (800-422-6237) if patients have search-related or other questions. Patients also can try a free clinical trials matching service, like those at the BreastCancerTrials.org, EmergingMed.com and ResearchMatch.org. However, it’s important to ask other such services if they charge a fee, where they get their clinical trials information, whether they keep personal information confidential or if they represent a drug brand or pharmaceutical company.

Jim Ferrell, 59, a retired police officer in Enumclaw, Wash., says he has enjoyed “an embarrassment of riches” since he received a diagnosis of stage 4 peripheral T-cell lymphoma, a rare disease, in 2008 and participated in a trial of the drug Istodax (romidepsin). To qualify for the trial, participants had to have undergone at least one prior therapy. Ferrell had received four cycles of a chemotherapy regimen, followed by four cycles of a different regimen. When an imaging test detected four cancerous nodes two months later, Ferrell and his doctor began exploring the clinical trial option.

I haven’t had a map, yet every turn I’ve taken has been the correct one, and every door I’ve reached has been unlocked.

Ferrell says Istodax has not only been highly effective against his disease, he also didn’t encounter any obstacles along the clinical trials path and remains lymphoma-free. Ferrell strongly encourages other cancer patients to take full advantage of databases and to enroll in a suitable trial, even if it means switching to a more supportive oncologist.

“I haven’t had a map,” he says, “yet every turn I’ve taken has been the correct one, and every door I’ve reached has been unlocked.”

Finding one or more trials for which a patient may be eligible is only half the battle. To determine whether a study is appropriate and the best choice, and to avoid any unwelcome surprises down the road, patients should gather as much information as possible by talking with their doctor and contacting the research team. Although studies have shown that cancer treatment expenses within and outside of clinical trials are about the same, insurance coverage varies: Patients could end up being billed for a study-related treatment, imaging test or doctor visit that falls outside the “routine care” definition. Physicians aren’t prepared to determine what a given insurer will or will not cover, says Howard Sandler, MD, chairman of radiation oncology at Cedars-Sinai Medical Center in Los Angeles. But oftentimes, he adds, patients can successfully appeal trial-related charges. The trial consent form should distinguish between standard and investigational procedures.

[Read "Understanding Clinical Trials"]

Beginning in 2014, a provision in the Patient Protection and Affordable Care Act (PPACA) requires individual and group health insurance plans implemented after 2013 to cover routine costs associated with approved clinical trials. Seventeen states and the District of Columbia have existing mandates that meet the PPACA provision: Alaska, Arizona, California, Colorado, Georgia, Indiana, Iowa, Kentucky, Maine, Massachusetts, Nevada, New Jersey, Ohio, Oregon, Tennessee, Texas and Vermont. 

Of course, if a study is located out of town, there are additional expenses—for transportation, accommodations, meals and the like—that insurance won’t cover. The American Cancer Society lists many outside sources of financial aid for these and other costs. (Visit cancer.org.) Patients might also check the Marti Nelson Cancer Foundation for a list of cancer-specific patient-advocacy groups and foundations, to see if they offer assistance. (Visit canceractionnow.org and click “Cancer Resources.”) Some entities, including the Lazarex Cancer Foundation (lazarex.org), earmark funds specifically for clinical trial enrollees.

There’s always an element of chance when it comes to dealing with cancer. But overcoming the hurdles associated with identifying and participating in a clinical trial depends more on determination and information-gathering than luck.

Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In